Glycation and glycosylation are non-enzymatic and enzymatic reactions, respectively, of glucose, glucose metabolites, and other reducing sugars with different substrates, such as proteins, lipids, and nucleic acids. Increased availability of glucose is a recognized risk factor for the onset and progression of diabetes-mellitus-associated disorders, among which cardiovascular diseases have a great impact on patient mortality. Both advanced glycation end products, the result of non-enzymatic glycation of substrates, and O-linked-N-Acetylglucosaminylation, a glycosylation reaction that is controlled by O-N-AcetylGlucosamine (GlcNAc) transferase (OGT) and O-GlcNAcase (OGA), have been shown to play a role in cardiovascular remodeling. In this review, we aim (1) to summarize the most recent data regarding the role of glycation and O-linked-N-Acetylglucosaminylation as glucose-related pathogenetic factors and disease markers in cardiovascular remodeling, and (2) to discuss potential common mechanisms linking these pathways to the dysregulation and/or loss of function of different biomolecules involved in this field.

Glycation and glycosylation in cardiovascular remodeling : focus on advanced glycation end products and O-linked glycosylations as glucose-related pathogenetic factors and disease markers / E. Dozio, L. Massaccesi, M.M. Corsi Romanelli. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 10:20(2021 Oct 19), pp. 4792.1-4792.25. [10.3390/jcm10204792]

Glycation and glycosylation in cardiovascular remodeling : focus on advanced glycation end products and O-linked glycosylations as glucose-related pathogenetic factors and disease markers

E. Dozio
Primo
;
L. Massaccesi;M.M. Corsi Romanelli
Ultimo
2021

Abstract

Glycation and glycosylation are non-enzymatic and enzymatic reactions, respectively, of glucose, glucose metabolites, and other reducing sugars with different substrates, such as proteins, lipids, and nucleic acids. Increased availability of glucose is a recognized risk factor for the onset and progression of diabetes-mellitus-associated disorders, among which cardiovascular diseases have a great impact on patient mortality. Both advanced glycation end products, the result of non-enzymatic glycation of substrates, and O-linked-N-Acetylglucosaminylation, a glycosylation reaction that is controlled by O-N-AcetylGlucosamine (GlcNAc) transferase (OGT) and O-GlcNAcase (OGA), have been shown to play a role in cardiovascular remodeling. In this review, we aim (1) to summarize the most recent data regarding the role of glycation and O-linked-N-Acetylglucosaminylation as glucose-related pathogenetic factors and disease markers in cardiovascular remodeling, and (2) to discuss potential common mechanisms linking these pathways to the dysregulation and/or loss of function of different biomolecules involved in this field.
advanced glycation end products (AGE); cardiac remodeling; diabetes; O-linked glycosylation; metabolic disorders; receptor for advanced glycation end products (RAGE)
Settore MED/05 - Patologia Clinica
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
19-ott-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
jcm-10-04792-v2.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 998.58 kB
Formato Adobe PDF
998.58 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/875698
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 12
social impact